Researcher1. You DON'T want Director buys! I COULD NOT DISAGREE5 Dec 2023 18:15
MORE!.
Give it a few days for the dust to settle and that is EXACTLY what this share needs IMHO! The low was what, about 9.5p about 3 weeks ago. Finally the sp is going in the right direction. I really think this is the start. Directors buying would underpin the sp.
On 9th November they launched the PD-L1 test to support cancer studies. Seems to be a "must have" as it is almost the only way to test for the level of PD-L1 biomarker on the surface of a cancer cell AFTER the original biopsy. Immunotherapy study Co's SUSPECT the level of PD-L1 is key to how well immunotherapy works, indeed maybe whether it works at all or not. After the original biopsy (possibly months before) there is no cut out tumour to test, obviously. So almost the ***ONLY WAY*** to find out the PD-L1 level during treatment/after is to use the parsortix machine to catch a circulating tumour cell and test THAT. It seems to me to be a ***MUST HAVE*** for for any cancer study that needs to find out the level of PD-1 before, during and after treatment.
Today they launched the Portrait+ CTC kit which makes analysing the cancerous cells harvested by the parsortix machine cheaper and less time consuming plus all Co's that choose to use this standard kit get their results the same way.
To me Angle are finally on their way. About time too!
All IMHO.